Management paper

EntreMed Executive Summary 1.1 History and Background EntreMed, Inc., Maryland founded in 1991 and publicly-traded since 1996 (NASDAQ: ENMD) a clinical-stage biopharmaceutical company developing therapeutics that "act on multiple cellular pathways involved in processes such as abnormal blood vessel growth, inflammation, coagulation, and programmed cell death"(entremed.com) Through a combination of both foresight and fortuity, EntreMed, in 1993, initiated its collaboration with Dr. Judah Folkman, the father of angiogenesis, who, more than 30 years ago, discovered that tumors were …showed first 75 words of 3247 total…

…showed last 75 words of 3247 total…Challener, C. (2003, February 24). Market reactions: Custom players offer their views from the trenches. Chemical Market Reporter. 8, FR3 Biotechnology - A Consistent Record of Growth, Biotechnology Industry Organization, www.bio.org Finding Funding - Opportunities and Caveats, About, Inc www.biotechabout.com Krause, C. (2003, March 17). Fewer financing opportunities in biotechnology sector has altered deal-making strategies. Chemical Market Reporter. 11, 12 Manufacturing, Human Genome Sciences, www.hgsi.com Scott, A. (2003, September 24). Biopharma manufacturing capacity comes into balance. Chemical Week. 33, 58